Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients

NCT ID: NCT01101217

Last Updated: 2010-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to study the effect of zinc supplementation in end stage renal failure on hemocystein level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

hemocystein increased in end stage renal failure and zinc involved in hemocystein metabolism thus zinc supplementation may be effective on hemocystein level.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo

placebo for 6 weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

placebo daily for 6 weeks

zinc

zinc sulfate 220 mg per day orally for 6 weeks

Group Type ACTIVE_COMPARATOR

Zinc Supplement

Intervention Type DRUG

in 50 patients zinc sulfate 220 mg per day orally for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zinc Supplement

in 50 patients zinc sulfate 220 mg per day orally for 6 weeks

Intervention Type DRUG

placebo

placebo daily for 6 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hemodialysis for 3 months
* older than 18 years old
* serum level of zinc less than 72.6 microgram/ l in men and less than 70 microgram/ l in female

Exclusion Criteria

* acute renal failre
* malabsorption
* history of steroid or cytotoxic consumption
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shiraz University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shiraz University of Medical Science

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shiraz University Hemodialysis Center

Shiraz, Fars, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4542

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Isoflavones and Peritoneal Dialysis
NCT04185168 COMPLETED NA